Clinical Trial Update: Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluated the combination of pozelimab and cemdisiran in adults with paroxysmal nocturnal hemoglobinuria who previously received pozeli…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• Cemdisiran (cemdisiran)
• Pozelimab

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Status: COMPLETED | Results posted: 2025-01-16